Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
109 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-06-01
Study Completion Date
2024-02-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Robotic-assisted hysterectomy is an alternative to laparoscopic surgery as part of a minimal invasive regimen. Several treatment strategies are followed to improve the overall outcome and minimize surgical stress. Glucocorticoids provide significant analgesic and antiemetic effects but its role in a fast-track, multi-modal setting is not settled when discharge is planned within 24-36 hours.
This study will evaluate in a randomized trial the effect of a single dose of 24 mg dexamethasone on women undergoing robotic-assisted hysterectomy with regard to surgical stress measured by c-reactive protein as primary outcome and, further, other stress markers like white blood cells. The postoperative recovery will be registered in validated charts and questionnaires for pain and analgesic use, quality of recovery, incontinence, sexual and work life. Furthermore, in a sub-analysis, transcriptional profiling will be applied to explore, which parts of the innate and cellular immune system is activated to explore the mechanisms of surgical stress response.
The hypothesis is that women undergoing robotic hysterectomy would benefit from peroperative glucocorticoid treatment on important life qualities like pain, fatigue, freedom of medications and resuming work and sexual activities. Further, future adjuvant peroperative regimens may be able to target the stress response in a more appropriate way
This study will evaluate in a randomized trial the effect of a single dose of 24 mg dexamethasone on women undergoing robotic-assisted hysterectomy with regard to surgical stress measured by c-reactive protein as primary outcome and, further, other stress markers like white blood cells. The postoperative recovery will be registered in validated charts and questionnaires for pain and analgesic use, quality of recovery, incontinence, sexual and work life. Furthermore, in a sub-analysis, transcriptional profiling will be applied to explore, which parts of the innate and cellular immune system is activated to explore the mechanisms of surgical stress response.
The hypothesis is that women undergoing robotic hysterectomy would benefit from peroperative glucocorticoid treatment on important life qualities like pain, fatigue, freedom of medications and resuming work and sexual activities. Further, future adjuvant peroperative regimens may be able to target the stress response in a more appropriate way
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of a Preoperative Single-dose Methylprednisolone on the Postoperative Rehabilitation After Abdominal Hysterectomy
NCT01106547
Hysterectomy
Methylprednisolone
Postoperative Pain
COMPLETED
PHASE4
Hysterectomy With Adnexal Surgery Procedures With the DEXTER Robotic System (The HYPER Study)
NCT06473675
Hysterectomy
COMPLETED
Recovery After Laparoscopic Hysterectomy With Deep Neuromuscular Blockade and Low Intra-abdominal Pressure
NCT01722097
Neuromuscular Blockade
Pain
Laparoscopy
COMPLETED
PHASE4
Testing of the Drug Tranexamic Acids as Prophylaxis of Bleeding in Benign Surgical Removal of the Uterus
NCT01940419
Gynecologic Surgical Procedures
Hysterectomy
Tranexamic Acid
COMPLETED
PHASE4
Local Anaesthesia and Remifentanil Sedation Versus Total Intravenous Anaesthesia for Hysteroscopic Surgery in an Ambulatory Surgery Department.
NCT00763789
Conscious Sedation
Remifentanil
Hysteroscopic Surgery
+2 more
UNKNOWN
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background Robotic operations in gynecology is one of the fastest growing fields in applied robotic technology.
In Denmark 4000 hysterectomies are performed each year on benign indications and minimal invasive techniques has risen from 35 to 80%. These operations consist of vaginal, laparoscopic assisted und the latest robotic assisted hysterectomy. Hysterectomy and prostate operations are the most common robotic assisted operations as an alternative to conventional laparoscopy.
Robotic surgery on benign indications in gynecology is still a discussion on the cost vs. benefit due to increased cost and lack of evidence on superiority in surgical outcome compared to conventional laparoscopy. For minimal invasive surgery is but a part of a complex series of treatment in a strategy, the so-called multi-modal regimen (1-7,16). By this, the day of discharge has dramatically decreased without compromising safety during surgery and postoperative recovery. However, not all single elements are proven for efficacy, let alone the specific targets for effect (16).
To further improve the overall outcome of surgery the surgical stress response are investigated, which includes inflammatory components and are of importance of postoperative pain and recovery (8,9,16). Here amongst others, glucocorticoids have proven to relieve pain in a number of procedures, applied in general surgery on colon, gallbladder, and breast, in orthopedic surgery on knee and breast surgery, and in gynecology, too, in laparoscopic hysterectomy (1-10,15,16). The dose of steroid to provide significant analgesic effect is, at least, dexamethasone of 0.1-0.2 mg/kg or 15 mg, which is substantiated in some reduction in inflammatory response (7,15,16). Glucocorticoids are known for analgesic, opioid-sparing and antiemetic effects but procedure-specific outcome are lacking. Similarly, the specific anti-inflammatory and sites of surgical stress-related responses are not well elucidated.
Aim The PhD study evaluate the effects of a single dose of steroid on acute postoperative stress response and pain after hysterectomy. The evaluation is on clinical relevant outcome that directly benefit the patients. We will measure surgical stress by c-reactive protein and other inflammatory markers based on transcriptional profiling, register pain and medication needed during hospital stay and after discharge, and when work and sexual function could be resumed.
Outcome The primary endpoint is reduction of postoperative c-reactive protein (crp) after robotic hysterectomy as an objective measurement of the stress amelioration by the given steroid. The rise postoperatively will be ascertained by two baseline measurements and every 4-6 hours after operation as long as the women is not discharged. The crp is not expected to be dependent on each operation team eagerness to perform well or the postoperative care to reach certain standards.
As secondary outcome we register pain scores from baseline to 24 h and later on, the postoperative analgesics medication from baseline to discharge and later on, quality of recovery (QoR-15D) in the latest 24 hours (12). Further, after discharge incontinence (ICIQ-UI), start of sexual life (PISQ-12/31), inflammatory markers, and resumption to recreational and work life will be ascertained in a diary. The baseline and early acute postoperative pain scores (visual analog scale, VAS) at rest and at movement (0-4 h postoperatively), late acute postoperative pain scores (VAS) at rest and at movement (24 h postoperatively); and cumulative opioid consumption (up to 24 h) will be registered. Part of blood samples will be stored for analysis of the cellular inflammatory systems by NanoString to explore the innate system and cellular activation (19,20). NanoString has the capacity to demonstrate activation of immune-related genes in the bloodstream during inflammatory induction and highlight an exciting role of immune competent cell in linking peripheral inflammation with immune activation and possibly anti-nociception. NanoString methodology investigates gene expression and currently quantifies the expression of 770 genes by determining the amount of messenger RNA (mRNA). mRNA is the end-product of gene transcription and, therefore, allows the study of gene up-regulation.
Monitoring cycles and levels of rest and activity will be done by an actigraph in a non-invasive method (13,14).
Hypothesis Women undergoing robotic hysterectomy would benefit from peroperative glucocorticoid treatment on important life qualities like pain, fatigue, freedom of medications and resuming work and sexual activities. Biological substrates such as inflammatory markers will be explored as underlying mechanism behind surgical stress response in order to direct perioperative medical interventions (19).
Perspectives and impact The randomized design will evaluate the effects of the single dose dexamethasone on the highest level of evidence. The anti-emetic effects of steroid are already incorporated in several guidelines on perioperative care; however, this study could further enhance our knowledge on minimal invasive surgery and optimize the treatment for surgical stress. The stress response in humans have evolved over millennia and is embedded in our genes but has no natural association with modern days surgery and may be ill placed and timely inadequate for recovery. The exploratory study may help identify pathways and specific mechanism in surgical stress that can be targeted in future to enhance women's recovery after surgery. The perspective is in further studies to target these specific sites in the immune activation.
Methods:
The PhD study in robotic hysterectomy will include a randomized trial with a single dose intravenously of 24 mg dexamethasone (Dexavit®) corresponding to 128 mg methyl prednisolone (Solumedrol®).
The randomization will be performed in Redcap and data stored the same place under each patient cpr.-no. but in a separate section. A person not involved in the project in any other form will perform the randomization. The patient will then receive the dose of either steroid or placebo saline intravenously, blinded to the patient and operation team (gynecology, operation ward and anesthesiology). The applicant PhD student will later enter the data in Redcap unknowing to the randomization results.
All women in the department operated by with a robotic assisted hysterectomy will be monitored and fill out a diary with validated questionnaires (names of quest.) to streamline the information gathering in a high flow work place and not to discriminate those outside of the project. These data will be presented as the drop-out analysis to evaluate the external validity of the trial. The flow of data collection is displayed below.
Sample size was calculated to be 49 women included in each arm on the primary outcome of c-reactive protein rising to the level of 40 mg/l with an expected reduction of 10 % a with a standard deviation of 7 calculated by https://clincalc.com/stats/samplesize.aspx (1,17,18). This may seem a parsimonious reduction but in practical terms, it translates to more than halving the need of opioids early and late postoperatively (2). On the assumption of incomplete data in less than 10 % of cases, 50 women in each group with complete data will be included. Robotic hysterectomy is a standard procedure in our department with about 80-90 hysterectomies each year, so we expect the study inclusion to last 1½-2 years.
Statistics Analysis are performed on the intention-to-treat principle with women on current use of analgesics as a subgroup analysis. The statistics will be unpaired and paired analysis (2-ways ANOVA) including relevant co-variates. Regression analysis will be performed with the primary outcome as dependent variable and the secondary outcomes and anthropometrics as dependent variable.
In Denmark 4000 hysterectomies are performed each year on benign indications and minimal invasive techniques has risen from 35 to 80%. These operations consist of vaginal, laparoscopic assisted und the latest robotic assisted hysterectomy. Hysterectomy and prostate operations are the most common robotic assisted operations as an alternative to conventional laparoscopy.
Robotic surgery on benign indications in gynecology is still a discussion on the cost vs. benefit due to increased cost and lack of evidence on superiority in surgical outcome compared to conventional laparoscopy. For minimal invasive surgery is but a part of a complex series of treatment in a strategy, the so-called multi-modal regimen (1-7,16). By this, the day of discharge has dramatically decreased without compromising safety during surgery and postoperative recovery. However, not all single elements are proven for efficacy, let alone the specific targets for effect (16).
To further improve the overall outcome of surgery the surgical stress response are investigated, which includes inflammatory components and are of importance of postoperative pain and recovery (8,9,16). Here amongst others, glucocorticoids have proven to relieve pain in a number of procedures, applied in general surgery on colon, gallbladder, and breast, in orthopedic surgery on knee and breast surgery, and in gynecology, too, in laparoscopic hysterectomy (1-10,15,16). The dose of steroid to provide significant analgesic effect is, at least, dexamethasone of 0.1-0.2 mg/kg or 15 mg, which is substantiated in some reduction in inflammatory response (7,15,16). Glucocorticoids are known for analgesic, opioid-sparing and antiemetic effects but procedure-specific outcome are lacking. Similarly, the specific anti-inflammatory and sites of surgical stress-related responses are not well elucidated.
Aim The PhD study evaluate the effects of a single dose of steroid on acute postoperative stress response and pain after hysterectomy. The evaluation is on clinical relevant outcome that directly benefit the patients. We will measure surgical stress by c-reactive protein and other inflammatory markers based on transcriptional profiling, register pain and medication needed during hospital stay and after discharge, and when work and sexual function could be resumed.
Outcome The primary endpoint is reduction of postoperative c-reactive protein (crp) after robotic hysterectomy as an objective measurement of the stress amelioration by the given steroid. The rise postoperatively will be ascertained by two baseline measurements and every 4-6 hours after operation as long as the women is not discharged. The crp is not expected to be dependent on each operation team eagerness to perform well or the postoperative care to reach certain standards.
As secondary outcome we register pain scores from baseline to 24 h and later on, the postoperative analgesics medication from baseline to discharge and later on, quality of recovery (QoR-15D) in the latest 24 hours (12). Further, after discharge incontinence (ICIQ-UI), start of sexual life (PISQ-12/31), inflammatory markers, and resumption to recreational and work life will be ascertained in a diary. The baseline and early acute postoperative pain scores (visual analog scale, VAS) at rest and at movement (0-4 h postoperatively), late acute postoperative pain scores (VAS) at rest and at movement (24 h postoperatively); and cumulative opioid consumption (up to 24 h) will be registered. Part of blood samples will be stored for analysis of the cellular inflammatory systems by NanoString to explore the innate system and cellular activation (19,20). NanoString has the capacity to demonstrate activation of immune-related genes in the bloodstream during inflammatory induction and highlight an exciting role of immune competent cell in linking peripheral inflammation with immune activation and possibly anti-nociception. NanoString methodology investigates gene expression and currently quantifies the expression of 770 genes by determining the amount of messenger RNA (mRNA). mRNA is the end-product of gene transcription and, therefore, allows the study of gene up-regulation.
Monitoring cycles and levels of rest and activity will be done by an actigraph in a non-invasive method (13,14).
Hypothesis Women undergoing robotic hysterectomy would benefit from peroperative glucocorticoid treatment on important life qualities like pain, fatigue, freedom of medications and resuming work and sexual activities. Biological substrates such as inflammatory markers will be explored as underlying mechanism behind surgical stress response in order to direct perioperative medical interventions (19).
Perspectives and impact The randomized design will evaluate the effects of the single dose dexamethasone on the highest level of evidence. The anti-emetic effects of steroid are already incorporated in several guidelines on perioperative care; however, this study could further enhance our knowledge on minimal invasive surgery and optimize the treatment for surgical stress. The stress response in humans have evolved over millennia and is embedded in our genes but has no natural association with modern days surgery and may be ill placed and timely inadequate for recovery. The exploratory study may help identify pathways and specific mechanism in surgical stress that can be targeted in future to enhance women's recovery after surgery. The perspective is in further studies to target these specific sites in the immune activation.
Methods:
The PhD study in robotic hysterectomy will include a randomized trial with a single dose intravenously of 24 mg dexamethasone (Dexavit®) corresponding to 128 mg methyl prednisolone (Solumedrol®).
The randomization will be performed in Redcap and data stored the same place under each patient cpr.-no. but in a separate section. A person not involved in the project in any other form will perform the randomization. The patient will then receive the dose of either steroid or placebo saline intravenously, blinded to the patient and operation team (gynecology, operation ward and anesthesiology). The applicant PhD student will later enter the data in Redcap unknowing to the randomization results.
All women in the department operated by with a robotic assisted hysterectomy will be monitored and fill out a diary with validated questionnaires (names of quest.) to streamline the information gathering in a high flow work place and not to discriminate those outside of the project. These data will be presented as the drop-out analysis to evaluate the external validity of the trial. The flow of data collection is displayed below.
Sample size was calculated to be 49 women included in each arm on the primary outcome of c-reactive protein rising to the level of 40 mg/l with an expected reduction of 10 % a with a standard deviation of 7 calculated by https://clincalc.com/stats/samplesize.aspx (1,17,18). This may seem a parsimonious reduction but in practical terms, it translates to more than halving the need of opioids early and late postoperatively (2). On the assumption of incomplete data in less than 10 % of cases, 50 women in each group with complete data will be included. Robotic hysterectomy is a standard procedure in our department with about 80-90 hysterectomies each year, so we expect the study inclusion to last 1½-2 years.
Statistics Analysis are performed on the intention-to-treat principle with women on current use of analgesics as a subgroup analysis. The statistics will be unpaired and paired analysis (2-ways ANOVA) including relevant co-variates. Regression analysis will be performed with the primary outcome as dependent variable and the secondary outcomes and anthropometrics as dependent variable.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Inflammatory Response
Pain, Postoperative
Nausea, Postoperative
Incontinence
Sexual Behavior
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Randomized, double blinded trial
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Blinded, results enteree into RedCap, logged and masked for participants
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dexamethasone
24 mg dexamethasone as single dose intravenously peroperatively
Group Type
ACTIVE_COMPARATOR
Dexamethasone phosphate
Intervention Type
DRUG
24 mg dexamethasone infused peroperatively
Placebo
saline infusion intravenously in a single dose
Group Type
PLACEBO_COMPARATOR
Placebo
Intervention Type
OTHER
Saline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexamethasone phosphate
24 mg dexamethasone infused peroperatively
Intervention Type
DRUG
Placebo
Saline
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
glucocorticoid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meno-metrorrhagia,
* dysmenorrhea,
* fibroma,
* dysplasia,
* dysmenorrhea,
* ability in Danish writing
* dysmenorrhea,
* fibroma,
* dysplasia,
* dysmenorrhea,
* ability in Danish writing
Exclusion Criteria
* current treatment with glucocorticoids, opioids and NSAID analgesics,
* diabetes,
* current treatment of malignant disease,
* renal or hepatic disease,
* unable to communicate in Danish language.
* diabetes,
* current treatment of malignant disease,
* renal or hepatic disease,
* unable to communicate in Danish language.
Minimum Eligible Age
18 Years
Maximum Eligible Age
85 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital of Southern Jutland
OTHER
Sponsor Role
collaborator
Herning Hospital
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Finn Lauszus
Associate Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Britta Frederiksen, PhD
Role: STUDY_CHAIR
Gyn. Dept. Aabenraa Hospital, Sygehus Sønderjylland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gyn. Dept.;Aabenraa Hospital, Sygehus Sønderjylland
Aabenraa, , Denmark
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Denmark
References
Explore related publications, articles, or registry entries linked to this study.
Lunn TH, Kristensen BB, Andersen LO, Husted H, Otte KS, Gaarn-Larsen L, Kehlet H. Effect of high-dose preoperative methylprednisolone on pain and recovery after total knee arthroplasty: a randomized, placebo-controlled trial. Br J Anaesth. 2011 Feb;106(2):230-8. doi: 10.1093/bja/aeq333. Epub 2010 Dec 3.
Reference Type
BACKGROUND
De Oliveira GS Jr, Almeida MD, Benzon HT, McCarthy RJ. Perioperative single dose systemic dexamethasone for postoperative pain: a meta-analysis of randomized controlled trials. Anesthesiology. 2011 Sep;115(3):575-88. doi: 10.1097/ALN.0b013e31822a24c2.
Reference Type
BACKGROUND
Jokela RM, Ahonen JV, Tallgren MK, Marjakangas PC, Korttila KT. The effective analgesic dose of dexamethasone after laparoscopic hysterectomy. Anesth Analg. 2009 Aug;109(2):607-15. doi: 10.1213/ane.0b013e3181ac0f5c.
Reference Type
BACKGROUND
Steinthorsdottir KJ, Kehlet H, Aasvang EK. Surgical stress response and the potential role of preoperative glucocorticoids on post-anesthesia care unit recovery. Minerva Anestesiol. 2017 Dec;83(12):1324-1331. doi: 10.23736/S0375-9393.17.11878-X. Epub 2017 Jun 12.
Reference Type
BACKGROUND
Lirk P, Thiry J, Bonnet MP, Joshi GP, Bonnet F; PROSPECT Working Group. Pain management after laparoscopic hysterectomy: systematic review of literature and PROSPECT recommendations. Reg Anesth Pain Med. 2019 Apr;44(4):425-436. doi: 10.1136/rapm-2018-100024. Epub 2019 Feb 3.
Reference Type
BACKGROUND
Wijk L, Nilsson K, Ljungqvist O. Metabolic and inflammatory responses and subsequent recovery in robotic versus abdominal hysterectomy: A randomised controlled study. Clin Nutr. 2018 Feb;37(1):99-106. doi: 10.1016/j.clnu.2016.12.015. Epub 2016 Dec 23.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Robotic surgery and steroid
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Transmuscular Quadratus Lumborum Block for Total Laparoscopic Hysterectomy.
NCT03650998
COMPLETED
PHASE4
Robot-assisted Laparoscopic Hysterectomy-RALH- Postoperative Complications, Quality of Life and Health Economics
NCT01761721
COMPLETED
Transversus Abdominis Plane Block After Robot-assisted Laparocopic Hysterectomy
NCT01504386
TERMINATED
PHASE4
Robotic MIS With Dexter
NCT05537727
COMPLETED
Disposable Energy Sources and Operating Room Time for Laparoscopic Hysterectomy
NCT02065453
COMPLETED
NA
Utilization of Uterine Manipulator in Abdominal Hysterectomy
NCT03943485
COMPLETED
NA
Same Day Discharge vs. Overnight Stay After Hysterectomy
NCT03627234
WITHDRAWN
NA
Analgesic Effects of US Bilateral Rectus Sheath Block for Laparoscopic GY Surgery
NCT02476799
COMPLETED
NA
Effect of Paracervical Block on Post Operative Pain in Laparoscopic Gynecologic Surgery
NCT01534416
COMPLETED
NA
Effect of Preoperative Rectus Sheath Block on Quality of Recovery in Single Port Laparoscopic Adnexal Surgery
NCT05984212
UNKNOWN
NA
Multimodal Pain Management After Robotic-Assisted Total Laparoscopic Hysterectomy
NCT04429022
COMPLETED
PHASE3
Hysterectomy - A Regional Intervention Study
NCT05255120
COMPLETED
NA
Importance of Surgical Approach for Gynecological Surgery on Metabolic Effects and Subsequent Recovery
NCT02291406
UNKNOWN
NA
Investigating the Optimal Remifentanil and Dexmedetomidine Concentration for Uterine Fibroid Ablation
NCT06640738
NOT_YET_RECRUITING
PHASE4
Pain and Hysteroscopy
NCT05316506
COMPLETED
NA
Fitostimoline Vaginal Pessaries in Women With Hysterectomy. Randomized, Perspective, Monoscentric Study.
NCT04612881
UNKNOWN
Robotic-assisted Hysterectomy: Single- vs. Multi-port Laparoscopic Access
NCT03373513
WITHDRAWN
NA
A Prospective Randomized Control Trial Comparing Immediate and 24-hours Delayed Catheter Removal Following Hysterectomy
NCT01182714
COMPLETED
NA
The Application of Vaginal Manipulator in Abdominal Hysterectomy Operations
NCT05420662
COMPLETED
NA
Safety Study of Use of Hyaluronic Acid Gel To Prevent Intrauterine Adhesions In Hysteroscopic Surgery
NCT01464528
UNKNOWN
EARLY_PHASE1
Role of Bladder Training During Post-operative Hospital Stay After Radical Hysterectomy in Patients
NCT01907646
COMPLETED
PHASE2
Intraperitoneal and Extraperitoneal Uterosacral Ligament Suspensions for Post-Hysterectomy Vaginal Vault Prolapse
NCT04172896
UNKNOWN
NA
Vaginal Vault Suspension During Benign Hysterectomy. A Questionnaire and Register-based Study.
NCT02859272
UNKNOWN
Local Anaesthetic Infusion For Laparoscopic Hysterectomy
NCT01291147
COMPLETED
PHASE4